, Volume 187, Issue 3, pp 312–320

The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine

  • Robert S. Kern
  • Michael F. Green
  • Barbara A. Cornblatt
  • J. Randall Owen
  • Robert D. McQuade
  • William H. Carson
  • Mirza Ali
  • Ron Marcus
Original Investigation



Cognitive deficits are a core feature of schizophrenia. As a target of intervention, improvements in cognition may lead to improvements in functional outcome.


The present paper is the first report, to our knowledge, on the neurocognitive effects of aripiprazole. Unlike other second-generation antipsychotics, aripiprazole is a D2 and D3 receptor partial agonist. It is unknown what effects this unusual pharmacological profile may yield on neurocognition.

Materials and methods

The present open-label study included data on 169 patients with schizophrenia or schizoaffective disorder who were randomly treated with aripiprazole or olanzapine. Subjects received a neurocognitive battery at baseline, week 8, and 26.


The aripiprazole group had a significantly greater dropout rate than the olanzapine group. Neurocognitive data were reduced through a principal components analysis that yielded a three-factor solution. The factors were general cognitive functioning, executive functioning, and verbal learning. For general cognitive functioning, both groups improved from baseline and the effects were relatively stable over the 26-week protocol. There were no differential treatment effects. For executive functioning, neither group improved significantly from baseline. For verbal learning, the aripiprazole group improved significantly from baseline to the 8th and 26th week of assessment, and there was a between-group effect favoring aripiprazole over olanzapine that was largely attributable to the differences in performance within the 8th week. Separate analyses were conducted for a measure of sustained attention (Continuous Performance Test–Identical Pairs). There were no differential treatment effects on this measure.


The findings from this open-label study suggest that the neurocognitive effects of aripiprazole are at least as good as those of olanzapine.


Schizophrenia Aripiprazole Olanzapine Neurocognition Learning Memory Dopamine Agonists 


  1. Aleman AA, Hijman R, de Haan EHF, Kahn RS (1999) Memory impairment in schizophrenia: a meta-analysis. Am J Psychiatr 156:1358–1366PubMedGoogle Scholar
  2. Army Individual Test Battery (1944) Manual of directions and scoring. War Department, Adjutant General’s Office, Washington, DCGoogle Scholar
  3. Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S et al (1996) Olanzapine versus placebo and haloperidol-acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14:111–123PubMedCrossRefGoogle Scholar
  4. Benton AL (1974) Revised visual retention test, 4th edn. The Psychological Corporation, San Antonio, TexasGoogle Scholar
  5. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA (2002) Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatr 159:1018–1028PubMedCrossRefGoogle Scholar
  6. Blair JR, Spreen O (1989) Predicting premorbid IQ: a revision of the National Adult Reading Test. Clin Neuropsychol 3:129–136CrossRefGoogle Scholar
  7. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381–389PubMedCrossRefGoogle Scholar
  8. Cornblatt BA, Lenzenweger MF, Dworkin RH, Erlenmeyer-Kimling L (1985) Positive and negative schizophrenic symptoms, attention, and information processing. Schizophr Bull 11:397–408PubMedGoogle Scholar
  9. Cornblatt BA, Risch NJ, Faris G, Friedman D, Erlenmeyer-Kimling L (1988) The continuous performance test, identical pairs version (CPT-IP). 1. New findings about sustained attention in normal-families. Psychiatry Res 26:223–238PubMedCrossRefGoogle Scholar
  10. Cohen J (1988) Statistical power analysis for the behavioral sciences. Erlbaum, Hillsdale, NJGoogle Scholar
  11. Delis DC, Kramer JH, Kaplan E, Ober BA (1987) The California Verbal Learning Test (manual). The Psychological Corporation, San Antonio, TXGoogle Scholar
  12. Gold JM (2004) Cognitive deficits as treatment targets in schizophrenia. Schizophr Res 72:21–28PubMedCrossRefGoogle Scholar
  13. Goldberg TE, Weinberger DR, Berman KF, Pliskin NH, Podd MH (1987) Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test. Arch Gen Psychiatry 44:1008–1014PubMedGoogle Scholar
  14. Gorsuch RL (1983) Factor analysis, 2nd edn. Erlbaum, Hillsdale, NJGoogle Scholar
  15. Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatr 153:321–330PubMedGoogle Scholar
  16. Green MF, Marshall BD Jr, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J (1997) Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatr 154:799–804PubMedGoogle Scholar
  17. Green MF, Kern RS, Braff DL, Mintz J (2000) Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the right stuff? Schizophr Bull 26:119–136PubMedGoogle Scholar
  18. Green MF, Kern RS, Heaton RK (2004) Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 72:41–51PubMedCrossRefGoogle Scholar
  19. Gueorguieva R, Krystal JH (2004) Move over ANOVA—progress in analyzing repeated-measures data and its reflection in papers published in the archives of general psychiatry. Arch Gen Psychiatry 61:310–317PubMedCrossRefGoogle Scholar
  20. Haggar C, Buckley P, Kenny JT, Freidman L, Ubogy D, Meltzer HY (1993) Improvement in cognitive function and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 34:702–712CrossRefGoogle Scholar
  21. Harvey PD, Keefe RS (2001) Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatr 158:176–184PubMedCrossRefGoogle Scholar
  22. Harvey PD, Bowie CR, Loebel A (2006) Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine. J Neuropsychiatry Clin Neurosci 18:54–63PubMedGoogle Scholar
  23. Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G (1993) Wisconsin Card Sorting Test manual revised and expanded. Psychological Assessment Resources, Odessa, FloridaGoogle Scholar
  24. Heinrichs RW, Zakzanis KK (1998) Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12:426–445PubMedCrossRefGoogle Scholar
  25. Hirano K, Imbens GW, Ridder G (2003) Efficient estimation of average treatment effects using the estimated propensity score. Econometrica 71:1161–1189CrossRefGoogle Scholar
  26. Hoff AL, Faustman WO, Wieneke M, Expinoza S, Costa M, Wolkowitz O, Csernansky JG (1996) The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology 15:361–369PubMedCrossRefGoogle Scholar
  27. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA (2002) The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441:137–140PubMedCrossRefGoogle Scholar
  28. Kaiser HF (1960) Directional statistical decisions. Psychol Rev 67:16–167CrossRefGoogle Scholar
  29. Kay SR, Opler LA, Fiszbein A (1992) Positive and negative syndrome scale (PANSS) manual. Multi-Health Systems, North Tonawanda, NYGoogle Scholar
  30. Keefe RSE, Silva SG, Perkins DO, Lieberman JA (1999) The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 25:201–222PubMedGoogle Scholar
  31. Kern RS, Green MF, Marshall BD Jr, Wirshing WC, Wirshing D, McGurk S, Marder SR, Mintz J (1999) Risperidone vs. haloperidol on secondary memory: can newer medications aid learning? Schizophr Bull 25:223–232PubMedGoogle Scholar
  32. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, Morita S (1995) 7-{4-[(2,3-Dichlorophenyl)-1-piperazinyl]butyoxy}-3,4-dihydro-2 (1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic and postsynaptic D2 receptor antagonist activity. J Pharmacol Exp Ther 274:329–336PubMedGoogle Scholar
  33. Lee MA, Thompson P, Meltzer HY (1994) Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 55(Suppl B):8–14Google Scholar
  34. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T (2003) Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61:123–126PubMedCrossRefGoogle Scholar
  35. Matthews CG, Klove H (1964) Instruction manual for the adult neuropsychology test battery. University of Wisconsin Medical School, Madison, WisconsinGoogle Scholar
  36. McQuade RD, Burris KD, Jordan S, Tottori K, Kurahashi N, Kikuchi T (2002) Aripiprazole: a dopamine-serotonin system stabilizer (abstract). Int J Neuropsychopharmacol 5(Suppl 1):S176Google Scholar
  37. McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH (2004) A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 65(Suppl 18):47–56PubMedGoogle Scholar
  38. Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233–255PubMedGoogle Scholar
  39. Nuechterlein KH, Dawson ME (1984) Information processing and attentional functioning in the developmental course of schizophrenia disorders. Schizophr Bull 10:160–203PubMedGoogle Scholar
  40. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK (2004) Identification of separable cognitive factors in schizophrenia. Schizophr Res 72:29–39PubMedCrossRefGoogle Scholar
  41. Nunnally JC (1967) Psychometric theory. McGraw-Hill, New YorkGoogle Scholar
  42. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Mirza A, Stock E, Stringfellow J, Ingenito G, Marder SR (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:681–690PubMedCrossRefGoogle Scholar
  43. Purdon SE, Jones BDW, Stip E, Labelle A, Addington D, David SR, Brier A, Tollefson GD (2000) Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 57:249–258PubMedCrossRefGoogle Scholar
  44. Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70:41–55CrossRefGoogle Scholar
  45. Rossi A, Mancini F, Stratta P, Mattei P, Gismondi R, Pozzi F et al (1997) Risperidone, negative symptoms, and cognitive deficit in schizophrenia: an open study. Acta Psychiatr Scand 95:40–43PubMedCrossRefGoogle Scholar
  46. SAS (1990) SAS Version 6.12. SAS Institute, Cary, NCGoogle Scholar
  47. Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM, Kester DB, Stafiniak P (1991) Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch Gen Psychiatry 48:618–624PubMedGoogle Scholar
  48. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu L-X, Sibley DR, Roth BL, Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400–1411PubMedCrossRefGoogle Scholar
  49. Spreen O, Benton AL (1977) Neurosensory center comprehensive examination for aphasia (NCCEA) (revised edition). University of Victoria, Neuropsychology Laboratory, Victoria, British ColumbiaGoogle Scholar
  50. Stip E, Remington GJ, Dursun SM, Reiss JP, Rotstein E, MacEwan GW, Chokka PR, Jones B, Dickson RA, Canadian Switch Study Group (2003) A Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine. J Clin Psychopharmacol 23:400–404PubMedCrossRefGoogle Scholar
  51. Wechsler D (1997) Wechsler Adult Intelligence Scale, 3rd edn. The Psychological Corporation, San Antonio, TXGoogle Scholar
  52. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005) A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8:457–472PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Robert S. Kern
    • 1
    • 2
    • 3
  • Michael F. Green
    • 1
    • 3
  • Barbara A. Cornblatt
    • 4
    • 5
  • J. Randall Owen
    • 6
  • Robert D. McQuade
    • 7
  • William H. Carson
    • 7
  • Mirza Ali
    • 8
  • Ron Marcus
    • 6
  1. 1.Department of Psychiatry and Biobehavioral SciencesGeffen School of Medicine at UCLALos AngelesUSA
  2. 2.VA Greater Los Angeles Healthcare Center (MIRECC 210A)Los AngelesUSA
  3. 3.Department of Veterans Affairs VISN 22Mental Illness Research, Education, and Clinical CenterLos AngelesUSA
  4. 4.Albert Einstein College of MedicineBronxUSA
  5. 5.Zucker Hillside HospitalNorth Shore-Long Island Jewish Health SystemGlen OaksUSA
  6. 6.Bristol-Myers Squibb CompanyWallingfordUSA
  7. 7.Otsuka America Pharmaceutical, IncorporatedPrincetonUSA
  8. 8.Otsuka Maryland Research InstituteRockvilleUSA

Personalised recommendations